文献速递血栓与止血

血友病的新型疗法

New therapies for hemophilia.
PubMed 文献 · Blood · 2018-12-17

血友病A和B是最常见的严重出血性疾病,替代治疗是主要手段,但患者仍面临治疗负担、突破性出血、关节病变和抑制剂发生等挑战。生物工程进展带来了给药更方便、免疫原性更低、疗效更好、半衰期更长的重组替代疗法;艾米珠单抗已获批用于伴或不伴抑制物的血友病A患者;靶向天然抗凝物的新化合物正在开发中。

要点

  • 重组生物工程改良的替代疗法给药更方便、免疫原性更低、疗效更好、半衰期更长。
  • 艾米珠单抗是一种双特异性抗体,作为血友病A的替代疗法,已获批用于伴或不伴抑制物的患者。
  • 靶向蛋白C、蛋白S、组织因子途径抑制物和抗凝血酶的新化合物正在开发中。

核心结论

  • 替代疗法和再平衡疗法为稳态止血控制提供了机会,且不暴露于免疫原性凝血因子蛋白。
  • 这些疗法可能在临床试验项目所研究的范围之外有更广泛的应用。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 血友病A和B患者仍经历沉重的治疗负担、突破性出血、进行性关节病以及高抑制剂发生率。
  • 重组生物工程已带来给药更方便、免疫原性更低、疗效更好、半衰期更长的替代疗法。
  • 艾米珠单抗已获批用于伴或不伴抑制物的血友病A患者。
  • 靶向蛋白C、蛋白S、组织因子途径抑制物和抗凝血酶的新化合物正在开发中。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A (HA) and hemophilia B (HB) are the most common severe bleeding disorders. Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding. Despite widespread availability of safe and effective replacement therapy, patients with HA and HB continue to experience a tremendous burden of treatment, breakthrough bleeding, and progressive joint disease, as well as high rates of inhibitor development. These remaining challenges are now being addressed by incredible advances in bioengineering. Recombinant bioengineering has led to replacement therapies with easier modes of administration, decreased immunogenicity, increased efficacy, and extended half-lives. Emicizumab, a bispecific antibody that acts as a substitutive therapy for HA, has been approved for patients with and without inhibitors. Novel compounds are in development to exploit the natural balance of hemostasis by targeting the natural anticoagulants protein C, protein S, tissue factor pathway inhibitor, and antithrombin. The substitution and rebalancing therapies provide an opportunity for steady-state hemostatic control without exposure to immunogenic clotting factor proteins. As such, they may have broader applications outside those being investigated in the clinical trial programs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2018. PMID: 30559264. doi:10.1182/blood-2018-08-872291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。